Key insights
- Guggenheim reiterated a Buy rating on Twist Bioscience (TWST) after Amazon launched an AI-powered drug discovery platform partnering with TWST. While the partnership isn't yet in TWST's guidance and the stock is near its 52-week high, the analyst views it as a benefit to screening companies like TWST. InvestingPro analysis suggests the stock is overvalued. The news is slightly bullish for TWST and potentially other biotech firms involved in drug screening.
Investing.com - Guggenheim reiterated a Buy rating and $55.00 price target on Twist Bioscience (NASDAQ:TWST) following Amazon’s launch of a new drug discovery platform. The stock currently trades at $57.41, already surpassing the analyst target and trading near its 52-week high of $59.
Amazon launched Amazon Bio Discovery on Wednesday, an AI-powered application designed to support antibody drug discovery and design. The platform partners with Twist Bioscience and DNA as integrated wet labs to synthesize and test lead candidates.
Data generated in the wet lab is fed back into the model for additional training and drug candidate refinement. Guggenheim analyst Subbu Nambi noted the development in maintaining the firm’s Buy rating on Twist Bioscience shares.
Twist Bioscience confirmed to Guggenheim that the Amazon partnership is brand new and just launched, so the company is watching it closely. The partnership is not yet captured in the company’s guidance.
Guggenheim’s key opinion leader check does not indicate strong conviction in superior commercial drugs coming from such a platform. The firm still views the development as a benefit to screening companies like Twist Bioscience.The stock has surged 81% year-to-date, though InvestingPro analysis indicates the shares are currently overvalued relative to its Fair Value. For investors seeking deeper insights, Twist Bioscience is among the 1,400+ US equities covered by comprehensive Pro Research Reports, which transform complex data into actionable intelligence.
In other recent news, Twist Bioscience Corporation reported its first-quarter earnings for fiscal year 2026, showing revenue of $103.7 million, which exceeded forecasts by 2.96%. However, the company’s earnings per share (EPS) fell short of expectations, coming in at -$0.50 compared to the forecasted -$0.43. Additionally, Twist Bioscience has entered into a licensing agreement with Invenra Inc. for the B-Body bispecific antibody platform, expanding its antibody discovery services. This agreement makes Twist a co-exclusive provider of the platform alongside Invenra. In governance matters, shareholders of Twist Bioscience approved director elections and executive compensation at the 2026 Annual Meeting, representing approximately 91.81% of the company’s outstanding shares eligible to vote. Meanwhile, Amazon introduced its Bio Discovery offering, providing researchers access to over 40 AI biology models to aid in drug discovery. This new platform allows scientists to accelerate research by combining computational design with wet-lab validation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.